Rapid Regression of Atherosclerosis with MTP Inhibitor Treatment

Overview

Journal Atherosclerosis

Publisher Elsevier

Specialty Cardiology & Vascular Diseases

Date 2013 Jan 22

PMID 23332773

Citations 25

Authors

Bernd Hewing

Saj Parathath

Christina K Mai

M Isabel Fiel

Liang Guo

Edward A Fisher

Affiliations

Soon will be listed here.

Abstract

Objective: Regression of atherosclerosis is a vital treatment goal of atherosclerotic vascular disease. Inhibitors of the microsomal triglyceride transfer protein (MTP) have been shown to reduce apolipoprotein B (apoB)-containing lipoproteins in animals and humans effectively. Therefore, the major aim of our study is to evaluate the effect of MTP inhibition on atherosclerotic plaque regression.

Methods: LDL-receptor-deficient (LDLr(-/-)) mice were fed a Western diet for 16 weeks and then harvested for baseline (n = 8), switched to chow diet (n = 8) or chow diet containing MTP inhibitor (BMS 212122; n = 8) for 2 weeks before harvesting.

Results: Treatment with MTP inhibitor led to rapid reduction in plasma lipid levels, which were accompanied by a significant decrease in lipid content and monocyte-derived (CD68+) cells in atherosclerotic plaques compared to baseline and chow diet control groups. MTP inhibitor-treated mice had increased collagen content, a marker associated with increased stability in human plaques. Furthermore, plaques of these mice showed a significant decrease in tissue factor and pro-inflammatory M1 macrophage marker monocyte chemoattractant protein-1 (MCP-I) and an increase in anti-inflammatory M2 macrophage markers arginase-I and mannose receptor 1 compared to mice in the baseline group.

Conclusion: Reversal of hyperlipidemia in atherosclerotic mice by inhibition of MTP leads to rapid and beneficial changes in the composition and inflammatory state of the plaque.

Citing Articles

Targeting Unc5b in macrophages drives atherosclerosis regression and pro-resolving immune cell function.

Schlegel M, Cyr Y, Newman A, Schreyer K, Barcia Duran J, Sharma M Proc Natl Acad Sci U S A. 2024; 121(44):e2412690121.

PMID: 39436659 PMC: 11536151. DOI: 10.1073/pnas.2412690121.

Deletion of Macrophage-Specific Glycogen Synthase Kinase (GSK)-3α Promotes Atherosclerotic Regression in Mice.

Patel S, Mastrogiacomo L, Fulmer M, Shi Y, Werstuck G Int J Mol Sci. 2022; 23(16).

PMID: 36012557 PMC: 9409307. DOI: 10.3390/ijms23169293.

Control of Cholesterol Metabolism Using a Systems Approach.

Formanowicz D, Radom M, Rybarczyk A, Tanas K, Formanowicz P Biology (Basel). 2022; 11(3).

PMID: 35336806 PMC: 8945167. DOI: 10.3390/biology11030430.

Pig and Mouse Models of Hyperlipidemia and Atherosclerosis.

Getz G, Reardon C Methods Mol Biol. 2022; 2419:379-411.

PMID: 35237978 DOI: 10.1007/978-1-0716-1924-7_24.

Oxidant resistant human apolipoprotein A-I functions similarly to the unmodified human isoform in delaying atherosclerosis progression and promoting atherosclerosis regression in hyperlipidemic mice.

Opoku E, Berisha S, Brubaker G, Robinet P, Smith J PLoS One. 2022; 17(2):e0259751.

PMID: 35120132 PMC: 8815868. DOI: 10.1371/journal.pone.0259751.

References

Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110(2):227-39. DOI: 10.1161/01.CIR.0000133317.49796.0E. View

Brautbar A, Ballantyne C . Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol. 2011; 8(5):253-65. DOI: 10.1038/nrcardio.2011.2. View

Nicholls S, Tuzcu E, Sipahi I, Grasso A, Schoenhagen P, Hu T . Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007; 297(5):499-508. DOI: 10.1001/jama.297.5.499. View

Trogan E, Feig J, Dogan S, Rothblat G, Angeli V, Tacke F . Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci U S A. 2006; 103(10):3781-6. PMC: 1450154. DOI: 10.1073/pnas.0511043103. View

Parathath S, Grauer L, Huang L, Sanson M, Distel E, Goldberg I . Diabetes adversely affects macrophages during atherosclerotic plaque regression in mice. Diabetes. 2011; 60(6):1759-69. PMC: 3114401. DOI: 10.2337/db10-0778. View

Feig J, Rong J, Shamir R, Sanson M, Vengrenyuk Y, Liu J . HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc Natl Acad Sci U S A. 2011; 108(17):7166-71. PMC: 3084076. DOI: 10.1073/pnas.1016086108. View

Nissen S, Nicholls S, Sipahi I, Libby P, Raichlen J, Ballantyne C . Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006; 295(13):1556-65. DOI: 10.1001/jama.295.13.jpc60002. View

Cuchel M, Bloedon L, Szapary P, Kolansky D, Wolfe M, Sarkis A . Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007; 356(2):148-56. DOI: 10.1056/NEJMoa061189. View

Lieu H, Withycombe S, Walker Q, Rong J, Walzem R, Wong J . Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion. Circulation. 2003; 107(9):1315-21. DOI: 10.1161/01.cir.0000054781.50889.0c. View

10.

Robl J, Sulsky R, Sun C, Simpkins L, Wang T, Dickson Jr J . A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors. J Med Chem. 2001; 44(6):851-6. DOI: 10.1021/jm000494a. View

11.

Durante W, Johnson F, Johnson R . Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol. 2007; 34(9):906-11. PMC: 1955221. DOI: 10.1111/j.1440-1681.2007.04638.x. View

12.

Gordon S, Taylor P . Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005; 5(12):953-64. DOI: 10.1038/nri1733. View

13.

Feig J, Parathath S, Rong J, Mick S, Vengrenyuk Y, Grauer L . Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation. 2011; 123(9):989-98. PMC: 3131163. DOI: 10.1161/CIRCULATIONAHA.110.984146. View

14.

Van Craeyveld E, Gordts S, Nefyodova E, Jacobs F, De Geest B . Regression and stabilization of advanced murine atherosclerotic lesions: a comparison of LDL lowering and HDL raising gene transfer strategies. J Mol Med (Berl). 2011; 89(6):555-67. PMC: 3098380. DOI: 10.1007/s00109-011-0722-x. View

15.

Wang L, Miller C, Swarthout R, Rao M, Mackman N, Taubman M . Vascular smooth muscle-derived tissue factor is critical for arterial thrombosis after ferric chloride-induced injury. Blood. 2008; 113(3):705-13. PMC: 2628377. DOI: 10.1182/blood-2007-05-090944. View

16.

Brunt E, Janney C, Di Bisceglie A, Neuschwander-Tetri B, Bacon B . Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999; 94(9):2467-74. DOI: 10.1111/j.1572-0241.1999.01377.x. View

17.

Ueshima K, Akihisa-Umeno H, Nagayoshi A, Takakura S, Matsuo M, Mutoh S . Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation. Biol Pharm Bull. 2005; 28(2):247-52. DOI: 10.1248/bpb.28.247. View

18.

Packard R, Libby P . Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2007; 54(1):24-38. DOI: 10.1373/clinchem.2007.097360. View

19.

Frick F, Bohlooly-Y M, Linden D, Olsson B, Tornell J, Eden S . Long-term growth hormone excess induces marked alterations in lipoprotein metabolism in mice. Am J Physiol Endocrinol Metab. 2001; 281(6):E1230-9. DOI: 10.1152/ajpendo.2001.281.6.E1230. View